Founded in 2016, Zhongsheng Tracing focuses on basic research and clinical translation of iPSC, committed to becoming a pioneer and leading brand in the industrialization of iPSC technology.
The company has established a product and service system covering the entire industry chain of iPSC technology upstream (iPSC reprogramming library and clinical level culture reagent products), midstream (iPSC induced differentiation of various functional cells for in vitro research), and downstream (iPSC derived cell drug development). It has internationally leading high standard scientific research and clinical level stem cell research and production facilities, as well as the largest Chinese population iPSC super donor library. At the same time, a systematic combination of invention patents has been established around the application of iPSC technology, covering areas such as reprogramming of iPSCs, directed induction of differentiation of multiple functional cells, production processes, and key raw materials.
Centered around the core technology of iPSC, Zhongsheng Tracing continues to promote the research and development of multiple types of cellular drug pipelines in the three major medical directions of anti-inflammatory repair, tumor immunity, and regenerative medicine. Among them, iPSC derived mesenchymal like cells (iMSCs) and iPSC derived natural killer cells (iNK) therapeutic products have both obtained clinical implied licenses from CDE, making them the first iMSC and iNK cell drugs approved for clinical use in China. The company's subsequent iPSC derived cell drugs will also gradually apply for IND and enter the clinical trial stage, continuously exploring the clinical value of iPSC derived drugs.